article thumbnail

Pharmaceutical drug delivery market and systems

Pharmaceutical Technology

Download our free, comprehensive list of the leading companies within the pharmaceutical drug delivery market.

article thumbnail

Why DTC isn’t, and is, marketing

World of DTC Marketing

CPG marketers are trying to maintain market share amid price increases and smaller product sizes, leading to a more significant jump in consumerism. But, in pharma marketing, the changes affect every product category. However, DTC marketing is different, much different. So what’s the opportunity for DTC marketers?

Marketing 252
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Juvisé licenses J&J’s MS drug Ponvory for marketing outside North America

Pharmaceutical Technology

The market for multiple sclerosis therapies is expected to be worth over $41bn by 2030, according to GlobalData.

Marketing 130
article thumbnail

5 things to look for in a marketing analytics partner

Bio Pharma Dive

Effective marketing measurement requires objectivity, connected data, transparency, a track record of innovation and a proven ability to execute.

Marketing 269
article thumbnail

Current and future players in the lupus market

Pharmaceutical Technology

As such, the SLE and LN marketplace is dominated by generics, and GSK’s Benlysta and AstraZeneca’s Saphnelo are the only drugs that have gained marketing approval specifically for SLE in more than 50 years. In previous years, Benlysta has managed to grow the lupus market in terms of value, having generated approximately $492.9m

Marketing 278
article thumbnail

Is biotech facing a long bear market?

Pharmaceutical Technology

Talks of a bear market in the biotech sector do not seem to pass, with news of companies falling into administration and layoffs becoming a recurrence. Just last week, trading for 4D Pharma , a British biotech, was suspended on the London Stock Exchange’s Alternative Investment Market , and the company will be delisted from NASDAQ on July 7.

Marketing 324
article thumbnail

Lilly market value soars on higher sales, obesity drug potential

Bio Pharma Dive

The Indianapolis drugmaker is now worth more than $500 billion, higher than any other pharmaceutical company, as analysts project lucrative markets for its obesity and Alzheimer's drugs.

Marketing 246